The SPAC market is showing new signs of pressure as four merger agreements have been called off over the past two weeks. That represents 36% of the year’s 11 terminations, all of which have come in the second half of the year, mostly from deals announced...read more
While there were no IPOs this past week, five SPACs went public ahead of the post-Labor Day rush. Casdin Capital and Corvex Management’s SPAC CM Life Sciences (CMLFU) upsized to raise $385 million. Led by the firms’ founders,...read more
Tailwind Acquisition, a blank check company formed by Casper CEO Philip Krim targeting a technology business, raised $300 million by offering 30 million units at $10. Each unit consists of one share of common stock and one-half of a warrant, exercisable at...read more
Three drug developers and a medical imaging company went public this past week, joined by eight SPACs. Preclinical protein degradation biotech Kymera Therapeutics (KYMR) upsized and priced above the range to raise $174 million at a $938...read more
Ripped blank checks: SPAC market sees bump in merger terminations
The SPAC market is showing new signs of pressure as four merger agreements have been called off over the past two weeks. That represents 36% of the year’s 11 terminations, all of which have come in the second half of the year, mostly from deals announced...read more
US IPO Weekly Recap: The September IPO market kicks off with a quiet week
While there were no IPOs this past week, five SPACs went public ahead of the post-Labor Day rush. Casdin Capital and Corvex Management’s SPAC CM Life Sciences (CMLFU) upsized to raise $385 million. Led by the firms’ founders,...read more
Casper CEO's tech SPAC Tailwind Acquisition prices $300 million IPO at $10
Tailwind Acquisition, a blank check company formed by Casper CEO Philip Krim targeting a technology business, raised $300 million by offering 30 million units at $10. Each unit consists of one share of common stock and one-half of a warrant, exercisable at...read more
US IPO Weekly Recap: Biotechs and SPACs ride the summer wave in a 4 IPO week
Three drug developers and a medical imaging company went public this past week, joined by eight SPACs. Preclinical protein degradation biotech Kymera Therapeutics (KYMR) upsized and priced above the range to raise $174 million at a $938...read more